|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The chi-square test indicated that high-level expression of C14ORF166 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage (P < 0.001), vital status (P = 0.026), tumor size (P = 0.034), serum squamous cell carcinoma antigen level (SCC-Ag; P = 0.035), and pelvic lymph node metastasis (P < 0.001).
|
26219895 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis revealed c14orf166 was an independent prognostic indicator of OS and DFS in all patients (P = 0.046, P = 0.006) and was associated with poor OS and DFS in the subgroups with advanced clinical stage (P = 0.037, P = 0.001), lymph node metastasis (P = 0.001, P < 0.001), and T3-T4 disease (P = 0.005, P = 0.001), respectively.
|
25964093 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
There was a significant difference in T stage, lymph node metastasis and TNM stage in patients categorized according to different C14orf166 expression levels.
|
28000881 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
High expression of C14orf166 was significantly associated with the T stage (<i>P</i>=0.006), lymph node metastasis (<i>P</i>=0.001), advanced TNM stage (<i>P</i><0.001), and chemotherapy (<i>P</i><0.001).
|
30126850 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
CLE-10 from <i>Carpesium abrotanoides</i> L. Suppresses the Growth of Human Breast Cancer Cells (MDA-MB-231) In Vitro by Inducing Apoptosis and Pro-Death Autophagy Via the PI3K/Akt/mTOR Signaling Pathway.
|
30897708 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
C14orf166 overexpression promoted breast cancer cell proliferation, whereas knockdown of C14orf166 inhibited this effect.
|
26883017 |
2016 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Finally, we find that high levels of CGI-99 are significantly correlated with STAT3 hyperactivation in breast cancer patients.
|
28166202 |
2017 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
C14orf166 overexpression promoted breast cancer cell proliferation, whereas knockdown of C14orf166 inhibited this effect.
|
26883017 |
2016 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Finally, we find that high levels of CGI-99 are significantly correlated with STAT3 hyperactivation in breast cancer patients.
|
28166202 |
2017 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
CLE-10 from <i>Carpesium abrotanoides</i> L. Suppresses the Growth of Human Breast Cancer Cells (MDA-MB-231) In Vitro by Inducing Apoptosis and Pro-Death Autophagy Via the PI3K/Akt/mTOR Signaling Pathway.
|
30897708 |
2019 |
|
Barrett Esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
The spacer sequence between the palindromic motifs is constant in length, but its sequence is highly variable among viral species, presenting a relaxed consensus (TT)GGKCCCY, which is similar to the Conserved Late Element or CLE (GTGGTCCC), a putative TrAP-responsive element.
|
30673741 |
2019 |
|
Barrett Esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
The frequency of GIN, methylation at E-cadherin and APC, and mAb Das-1 reactivity in Group BE was significantly higher than that in Group CLE (p < 0.0001, p < 0.0001 and p < 0.005, and p < 0.0001, respectively).
|
19048617 |
2009 |
|
Nasopharyngeal carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
CLE is a suitable and valid method for otolaryngologists to diagnose of NPC in vivo.
|
30151887 |
2019 |
|
Nasopharyngeal carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analyses revealed 104/109 (95.4 %) of the NPC tissue samples expressed c14orf166.
|
25964093 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that C14orf166 promotes bladder cancer cell proliferation and can be a novel prognostic biomarker for patients with bladder cancer.
|
26905879 |
2016 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that C14orf166 promotes bladder cancer cell proliferation and can be a novel prognostic biomarker for patients with bladder cancer.
|
26905879 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Then, the correlations between the C14orf166 expression levels and the clinicopathological features of NSCLC were analyzed.
|
30126850 |
2018 |
|
Malignant tumor of cervix
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the expression and clinicopathological significance of C14ORF166 in cervical cancer.
|
26219895 |
2016 |
|
Chilblains
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The highest mean pruritus intensity was reported by subjects with hypertrophic LE (5.1 ± 3.0 points) followed by generalized discoid LE (3.6 ± 3.0 points), subacute CLE (3.0 ± 3.0 points), chilblain LE (3.0 ± 1.0 points), localized discoid LE (2.6 ± 2.0 points), intermittent CLE (2.6 ± 3.0 points), acute CLE (2.5 ± 1.2 points), and lupus erythematosus profundus (1.9 ± 2.7 points).
|
30148164 |
2018 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, acute CLE and HIIE did not stimulate significant HPC mobilisation in CHD, although both exercise modes elevated circulating concentrations of sympathetic activation.
|
29933914 |
2019 |
|
Crohn Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aims of this pilot study performed in patients with CD after ileocolonic resection were to compare the macroscopic appearance of the neoterminal ileum, according to the endoscopic Rutgeerts score, with the microscopic findings provided by CLE 6 to 12 months after surgery and to assess the predictive values of CLE-generated parameters for predicting further recurrence in patients with postoperative endoscopic remission.
|
30849396 |
2019 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which 70% of patients experience disfiguring skin inflammation (grouped under the rubric of cutaneous lupus erythematosus [CLE]).
|
30745462 |
2019 |
|
Dermatomyositis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Some recent data have indicated that it may also be associated with autoimmune connective tissue diseases, including systemic sclerosis and dermatomyositis; however, studies on the prevalence and clinical characteristics of pruritus in CLE are limited.
|
30148164 |
2018 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings reveal novel mechanisms by which polyphenolic extracts from ABE, LGE and especially CLE target the gut-liver axis to protect diet-induced obese mice against metabolic endotoxaemia, insulin resistance and hepatic steatosis, which importantly improves hepatic insulin clearance.
|
29270816 |
2018 |
|
Lupus Erythematosus, Cutaneous
|
0.010 |
Biomarker
|
disease |
BEFREE |
Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which 70% of patients experience disfiguring skin inflammation (grouped under the rubric of cutaneous lupus erythematosus [CLE]).
|
30745462 |
2019 |